Skip to main content

Table 2 Within-group and intergroup comparison of clinical findings

From: Comparison of the efficacy of once- and twice-daily colchicine dosage in pediatric patients with familial Mediterranean fever – a randomized controlled noninferiority trial

  Once-daily dosage group (n = 42)   Twice-daily dosage group (n = 37)   
  Baseline First visit Second visit p Valuea Baseline First visit Second visit p Valuea p Valueb
Features of disease          
 Fever >38 °C, % 66.7 21.4 19 <0.001 54.1 22.2 16.7 0.001 0.272
 Duration of attacks, h (mean ± SD) 48.00 ± 27.25 12.31 ± 25.18 8.4 ± 21.77 <0.001 44.57 ± 31.42 12.35 ± 24.08 5.6 ± 15.13 <0.001 0.711
 Number of attacksc 3 (3–10)d 0 (0–1) 0 (0–1) <0.001 3 (4–10)d 0 (0–1) 0 (0–0) <0.001 0.521
 Erysipelas-like erythema, % 7.1 0 4.8 0.174 5.4 0 0 0.135 0.383
Skeletal system manifestations          
 Arthralgia, % 35.7 21.4 4.8 0.001 51.4 24.3 8.1 <0.001 0.376
 Arthritis, % 26.2 2.4 2.4 <0.001 24.3 8.1 0 0.003 0.948
Serosal involvement          
 Abdominal pain, % 69 23.8 21.4 <0.001 64.9 24.3 21.6 <0.001 0.840
 Chest pain, % 31 4.8 4.8 <0.001 18.9 2.7 2.7 0.002 0.142
Systemic manifestations          
 Malaise, % 64.3 26.2 14.3 <0.001 51.4 24.3 21.6 0.002 0.726
 Headache, % 40.5 23.8 14.3 0.002 37.8 16.2 10.8 0.002 0.553
 Confinement to bed during attacks, % 42.9 4.8 0 <0.001 37.8 0 2.7 <0.001 0.505
  1. aMedian (min-max)
  2. b p value for within-group comparison of manifestations before and after colchicine treatment
  3. c p value for intergroup comparison of manifestations
  4. dMedian number of attacks in the 6 months before admission